BRAF and melanoma: The application of targeted therapy, including BRAF inhibitors (e.g., vemurafenib (VEM) and debrafenib) and mitogen-activated protein kinase kinase (MEK) inhibitors (e.g., trametinib (TRA) and cobimetinib), was regarded as a therapeutic breakthrough when used in patients with BRAF-mutated melanoma [3].